Status:

COMPLETED

Increased Emotional-motivational Processing in Patients with Chronic Pain and Its Neural Correlates

Lead Sponsor:

susanne becker

Collaborating Sponsors:

SNSF

Conditions:

Chronic Pain

Low Back Pain

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

Chronic pain causes immense suffering and reductions in quality of life as well as enormous socioeconomic costs. Very many chronic pain patients fall into the category of unspecific pain, i.e. pain wi...

Detailed Description

Chronic pain is a major personal and societal problem causing immense suffering and reductions in quality of life as well as enormous socioeconomic costs (e.g. estimated as 11.2 Mio CHF of direct and ...

Eligibility Criteria

Inclusion

  • HEALTHY PARTICIPANTS
  • Inclusion criteria:
  • Between 18 and 70 years of age (in Substudy 1: age- and sex-matched to chronic pain patients)
  • Good overall health status
  • Sufficient knowledge of German or English to follow instructions
  • Ability to give written informed consent
  • Exclusion criteria:
  • Pain longer than \>3 consecutive days and on more than 30 days within the last 12 months
  • Major psychiatric or neurological disorders, and substance abuse
  • Consumption of alcohol, illegal drugs, and analgesic drugs within 24 hours before testing
  • Pregnancy
  • For Substudy 2: An MR-specific safety questionnaire will be filled in to check for any contradiction to magnetic resonance imaging (MRI): wearing an electronic device, implants or prosthetics, injury from metal parts or fragments, metal parts in or on the body, surgery on the head, heart or back, tattoo or permanent makeup, problems lying still for long periods of time, claustrophobia, possible pregnancy, metal contraceptive coil
  • CHRONIC PAIN PATIENTS
  • Inclusion criteria:
  • Between 18 and 70 years of age
  • Unspecific musculoskeletal pain as defined according to the ICD-11 as chronic primary pain (MG30.1, e.g. chronic widespread pain, complex regional pain syndrome, chronic primary headache or orofacial pain, chronic migraine, chronic tension-type headache, trigeminal autonomic cephalalgias, burning mouth syndrome, chronic primary visceral pain, irritable bowel syndrome, chronic primary musculoskeletal pain), and which is not classified as chronic cancer related pain (MG30.2; e.g. chronic cancer pain, chronic post-cancer treatment pain), chronic postsurgical or post traumatic pain (MG30.3; e.g. chronic postsurgical pain, chronic posttraumatic pain), chronic secondary musculoskeletal pain (MG30.4; e.g. chronic musculoskeletal pain from persistent inflammation, chronic musculoskeletal pain associated with structural changes, chronic musculoskeletal pain associated with a disease of the nervous system), chronic secondary visceral pain (MG30.5; e.g. chronic visceral pain from persistent inflammation, chronic visceral pain from vascular mechanisms, chronic visceral pain from mechanical factors), chronic neuropathic pain (MG30.6; e.g. chronic peripheral neuropathic pain, trigeminal neuralgia, postherpetic neuralgia, chronic central neuropathic pain), chronic secondary headache or orofacial pain (MG30.7; e.g. chronic dental pain, chronic neuropathic orofacial pain, trigeminal neuralgia, headache or orofacial pain attributed to chronic secondary temporo-mandibular disorders), other specified chronic pain (MG30.Y), or other non-specified chronic pain (MG30.Z)
  • Sufficient knowledge of German or English to follow instructions
  • Ability to give written informed consent
  • Exclusion criteria:
  • Major psychiatric or neurological disorders, and substance abuse
  • Regular intake of opioids for pain (e.g. burprenorphine, codeine, fentanyl, hydromorphone, orphine, oxycodone, tapentadol, tilidine/na-loxone, tramadol)
  • Consumption of alcohol, illegal drugs, and analgesic drugs within 24 hours before testing
  • Pregnancy

Exclusion

    Key Trial Info

    Start Date :

    April 6 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    April 5 2024

    Estimated Enrollment :

    138 Patients enrolled

    Trial Details

    Trial ID

    NCT05257356

    Start Date

    April 6 2022

    End Date

    April 5 2024

    Last Update

    February 11 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Balgrist Campus

    Zurich, Canton of Zurich, Switzerland, 8008